Evidence map›Paper›PMID 41132675›Full record

ReviewFrontiers in immunology2025

Is the MAPK ERK5 the nexus from FAO to NK cell-mediated metastasis immune surveillance?

Martin Villalba, Delphine Gitenay, Sara Zemiti, Jean-François Rossi, Mauricio Campos-Mora

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Translational cancer research · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin VillalbaIRMB, Univ Montpellier, INSERM, CHU Montpellier, CNRS, Montpellier, France.
Delphine GitenayIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
Sara ZemitiIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
Jean-François RossiInstitut du Cancer Avignon-Provence Sainte Catherine, Avignon, France.
Mauricio Campos-MoraIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammalian cells adapt to their environment by reshaping their metabolism. Increased fatty acid oxidation (FAO) enables metastatic cells to enhance their motility and colonize new niches, where the fatty acid transporter CD36 functions as both marker and driver of this process. The MAPK ERK5 regulates CD36 expression, FAO, and the epithelial-mesenchymal transition (EMT), a critical initial step in metastasis. Contrary to popular belief, metastasis is a highly inefficient process, in part due to natural killer (NK) cell immune surveillance. This cytotoxic lymphocyte lineage detects inhibitory and activating ligands on target cells to determine their fate. During EMT, the expression of specific ligands on metastatic cells triggers their recognition by NK cells. Interestingly, several of these ligands are regulated by ERK5. We hypothesize that ERK5 may serve as a central link between FAO, metastasis, and immune surveillance. Here, we review current knowledge and available evidence regarding ERK5 expression in tumor cells and its role in cancer cell migration and metastasis and speculate in the potential role of ERK5 in immune recognition and the clearance of metastasis by NK cells.

Indexed as

Immunologic SurveillanceKiller Cells, NaturalMitogen-Activated Protein Kinase 7NeoplasmsAnimalsCell MovementEpithelial-Mesenchymal TransitionHumansNeoplasm MetastasisMitogen-Activated Protein Kinase 7CD36epithelial-mesenchymal transition (EMT)Erk5fatty acid oxidation (FAO)immune surveillancenatural killer (Nk) cell

Identifiers

PMID41132675
PMCPMC12540394

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.